NCT00510224View on ClinicalTrials.gov

Sandostatin for Patients With Androgen Independent Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

Sandostatin

Sandostatin 30mg intramuscular every 28 days

Trial Locations (1)

94115

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER